Brokerages expect Reata Pharmaceuticals, Inc. (NASDAQ:RETA) to announce sales of $12.58 million for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Reata Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $12.44 million and the highest estimate coming in at $12.73 million. Reata Pharmaceuticals posted sales of $12.37 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 1.7%. The firm is scheduled to announce its next earnings report on Thursday, August 10th.

According to Zacks, analysts expect that Reata Pharmaceuticals will report full year sales of $12.58 million for the current financial year, with estimates ranging from $44.60 million to $50.92 million. For the next fiscal year, analysts anticipate that the business will post sales of $50.64 million per share, with estimates ranging from $50.37 million to $50.92 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow Reata Pharmaceuticals.

Several brokerages have recently weighed in on RETA. Robert W. Baird reissued an “outperform” rating and issued a $47.00 price target (up previously from $43.00) on shares of Reata Pharmaceuticals in a research note on Tuesday, July 25th. Stifel Nicolaus reissued a “buy” rating and issued a $50.00 price target (up previously from $38.00) on shares of Reata Pharmaceuticals in a research note on Tuesday, July 25th. Citigroup Inc. reissued a “buy” rating and issued a $87.00 price target (up previously from $39.00) on shares of Reata Pharmaceuticals in a research note on Tuesday, July 25th. Ladenburg Thalmann Financial Services reissued a “buy” rating and issued a $61.00 price target (up previously from $55.00) on shares of Reata Pharmaceuticals in a research note on Wednesday, July 26th. Finally, Zacks Investment Research cut Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, July 18th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $55.83.

COPYRIGHT VIOLATION NOTICE: “Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Expected to Post Quarterly Sales of $12.58 Million” was posted by Daily Political and is owned by of Daily Political. If you are reading this article on another website, it was illegally copied and republished in violation of international trademark and copyright laws. The original version of this article can be read at https://www.dailypolitical.com/2017/08/05/reata-pharmaceuticals-inc-nasdaqreta-expected-to-post-quarterly-sales-of-12-58-million.html.

In other Reata Pharmaceuticals news, Director James Edward Bass bought 8,064 shares of the firm’s stock in a transaction that occurred on Tuesday, August 1st. The stock was acquired at an average price of $31.00 per share, with a total value of $249,984.00. Following the completion of the purchase, the director now directly owns 67,411 shares of the company’s stock, valued at approximately $2,089,741. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder A/S Novo sold 61,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 14th. The stock was sold at an average price of $25.11, for a total value of $1,531,710.00. Following the sale, the insider now directly owns 642,405 shares of the company’s stock, valued at approximately $16,130,789.55. The disclosure for this sale can be found here. Insiders have sold 471,886 shares of company stock valued at $12,541,056 in the last ninety days. 62.40% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC raised its position in shares of Reata Pharmaceuticals by 19.5% in the first quarter. Geode Capital Management LLC now owns 63,778 shares of the company’s stock valued at $1,444,000 after buying an additional 10,397 shares during the last quarter. Fifth Third Bancorp purchased a new position in shares of Reata Pharmaceuticals during the first quarter valued at about $395,000. RGT Capital Management Ltd. purchased a new position in shares of Reata Pharmaceuticals during the first quarter valued at about $1,347,000. FMR LLC raised its position in shares of Reata Pharmaceuticals by 40.6% in the first quarter. FMR LLC now owns 237,606 shares of the company’s stock valued at $5,382,000 after buying an additional 68,600 shares during the last quarter. Finally, Atlantic Trust Group LLC purchased a new position in shares of Reata Pharmaceuticals during the first quarter valued at about $285,000. Institutional investors and hedge funds own 41.63% of the company’s stock.

Reata Pharmaceuticals (NASDAQ RETA) traded down 2.84% on Wednesday, reaching $28.73. The company’s stock had a trading volume of 199,344 shares. The company’s market cap is $642.55 million. The company has a 50-day moving average price of $30.77 and a 200 day moving average price of $25.85. Reata Pharmaceuticals has a 12 month low of $15.17 and a 12 month high of $41.60.

Reata Pharmaceuticals Company Profile

Reata Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases.

Get a free copy of the Zacks research report on Reata Pharmaceuticals (RETA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Reata Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.